This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
Development PipelineSGN-EGFRd2
an investigational bispecific gamma delta (γδ)-T cell engager directed to EGFR
The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Clinical Trials
SGNEGFRd2-001: Advanced solid tumors
-
Phase 1
-
Phase 2
-
Phase 3
Program Resources
Related Links